Ypsomed is the leading independent developer and manufacturer of user-friendly self-injection systems.
You have successfully submitted your enquiry. Someone from our company will respond ASAP
Ypsomed is the leading independent developer and manufacturer of user-friendly self-injection systems. To complement our innovative and reliable pen systems for the injection of insulin, hGH, FSH and PTH provides a complete range of dual-chamber pen and syringe-based auto-injector platforms for monodose injections.
Ypsomed unique ‘click-on’ pen needles and safety pen needles are compatible with our own and all other widely available pens. A broad-based technology platform and over 250 patent families mean Ypsomed can meet virtually all customer needs in the growing market for self-injection systems.
In this article, Thomas Fontanellaz, Reto Jost, and Andreas Schneider, all at Ypsomed, discuss how the company is addressing the growing need for subcutaneous injections that accommodate higher volumes and viscosities.
Andreas Schneider and Jakob Lange of Ypsomed consider the subcutaneous administration of larger volumes of biopharmaceuticals in the pharmaceutical industry.
Lorenzo Biasio and Gloria Skibba, both at Ypsomed, discuss the integration of the company’s Net Zero Program into its self-injection platforms and explain how YpsoMate 1 and 2.25 mL autoinjectors have been redesigned to achieve a lower carbon footprint.
Thomas Blaser of Ypsomed and Dr Maëlle Douaire of BD explore how drug viscosity, autoinjectors and syringes affect the administration of injectable therapies, demonstrating the results of a study evaluating combined autoinjectors and syringes from the two companies that provide efficient and smooth delivery of high-dose therapies.
Philipp Richard of Ypsomed scrutinises the efficient production of self-injection devices in the pharma industry and describes Ypsomed’s own platforms for developing these devices, highlighting the need to be adaptable and resilient to the rapidly evolving world of drug development.
At its Capital Markets Day at Ypsomed’s manufacturing plant in Schwerin, Germany, on Monday, September 29, 2025, Ypsomed announced its key strategic priorities and mid-term ambition.
Ypsomed celebrated the topping-out ceremony for its second plant in Schwerin with over 200 guests from politics, business, and the construction trade.
Ypsomed will establish its first manufacturing facility in the US. The company has selected Holly Springs in Wake County, North Carolina, as the location, and will invest around CHF200m in a first phase.
Ypsomed launches YpsoLoop, the first autoinjector platform designed for circularity. The two new 1 ml and 2ml platform versions enable material recovery through a design enabling automated disassembly and efficient recycling, while offering the convenience of a pre-filled, two-step autoinjector.
Ypsomed (SIX: YPSN) continued on its growth trajectory in the first half of the 2025/26 financial year, as the Delivery Systems business reached CHF266.6m of sales.
Romaco has developed the first Siebler StripTabs™ line for Indian contract manufacturer ANKUR Drugs and Pharma Ltd. The system's innovative design was specially created for the production and packaging of pharmaceutical film tablets. For the first time, this novel drug delivery sy
The Contite measuring cell proves its unbeatable advantages At customers’ premises, our instruments are actually on the test bench day by day – Deltapilot S FMB70, however, has recently passed a special test. Developed for the requirements of the pharmaceutical and hygiene industry it s
Since product quality is often affected by the environmental conditions in a clean room, it is essential to monitor critical parameters such as particle concentration,temperature, differential pressure and humidity. In addition air flow (speed and direction) and door interlocking must be contro
YpsoLoop is a paradigm-shifting circular solution. It is a convenient, pre-filled, two-step, single-use device that enables material recovery through automated disassembly and efficient recycling.
YpsoFlow is a spring-driven, pre-filled pen platform for GLP-1 and peptide therapies, which delivers doses of up to 0.80mL with a low-force mechanism and audible dose feedback.
Larger volume capability, delivering doses of up to 1.0mL – five times more than comparable models with similar handling mechanisms – making it ideal for higher-dose therapies.
The YpsoMate autoinjector is an automated injection device for 1mL pre-filled glass or polymer syringes intended for all patient groups.
YpsoMate 2.25 and YpsoMate 2.25 Pro autoinjectors are automated injection devices for 2.25 mL pre-filled glass or polymer syringes and intended for all patient groups.
YpsoMate 5.5 autoinjector is an automated injection device for 5.5mL pre-filled glass syringes, intended for all patient groups.
The UnoPen is an easy-to-use variable-dose pen designed for insulin, GLP-1, and other multidose therapies, delivering familiar handling that supports strong patient acceptance.
YpsoDose is the pre-filled, ready-to-use patch injector intended for subcutaneous delivery of volumes up to 10mL.
High-tech manufacturing of our flagship pen platform UnoPen, the intuitive dial & dose pre-filled pen.
The pre-filled, ready-to-use patch injector is designed for subcutaneous delivery of volumes up to 10mL.
High-tech manufacturing of our flagship autoinjector platform YpsoMate, the two-step intuitive autoinjector.
The award-winning autoinjector uniting sustainability and patient convenience.
An overview of our products, services and innovations. Ypsomed is the reliable partner for self-care solutions.
The 5.5ml large volume autoinjector takes handheld self-injection beyond volumes of 2.0ml.
